Company intelligence / Profile preview
Granata Bio
- Ownership
- Private
- Employees
- ~9
- Development stage
- Commercial
Overview
Granata Bio commercializes FDA-approved fertility drugs such as MILOPHENE and develops additional infertility therapeutics. The company recently expanded its portfolio by acquiring Oviva Therapeutics and its first-in-class candidate OVI‑586 targeting ovarian aging. The pipeline includes both marketed drugs and late-stage clinical candidates focused on improving access to fertility treatments.
- Therapeutic areas
- Women's Health
- Modalities
- Small molecules (e.g., clomiphene citrate)Biologics/peptides (e.g., menotropins for injection)Novel therapeutics for ovarian function (from Oviva acquisition)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Granata Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Granata Bio.